Literature DB >> 10925241

Can we produce a human corneal equivalent by tissue engineering?

L Germain1, P Carrier, F A Auger, C Salesse, S L Guérin.   

Abstract

Tissue engineering is progressing rapidly. Bioengineered substitutes are already available for experimental applications and some clinical purposes such as skin replacement. This review focuses on the development of reconstructed human cornea in vitro by tissue engineering. Key elements to consider in the corneal reconstruction, such as the source for epithelial cells and keratocytes, are discussed and the various steps of production are presented. Since one application of this human model is to obtain a better understanding of corneal wound healing, the mechanisms of this phenomenon as well as the function played both by membrane-bound integrins and components from the extracellular matrix have also been addressed. The analysis of integrins by immunohistofluorescence labelling of our reconstructed human cornea revealed that beta(1), alpha(3), alpha(5), and alpha(6) integrin subunits were expressed but alpha(4) was not. Laminin, type VII collagen and fibronectin were also detected. Finally, the future challenges of corneal reconstruction by tissue engineering are discussed and the tremendous applications of such tissue produced in vitro for experimental as well as clinical purposes are considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10925241     DOI: 10.1016/s1350-9462(00)00005-7

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  32 in total

Review 1.  Stem cell and precursor cell therapy.

Authors:  Jingli Cai; Mahendra S Rao
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

2.  Biosynthetic corneal substitute implantation in dogs.

Authors:  Ellison Bentley; Christopher J Murphy; Fengfu Li; David J Carlsson; May Griffith
Journal:  Cornea       Date:  2010-08       Impact factor: 2.651

3.  Preparation and physical properties of a novel biocompatible porcine corneal acellularized matrix.

Authors:  Yi Shao; Luowa Quyang; Yueping Zhou; Jing Tang; Yuehui Tan; Qiuping Liu; Zhirong Lin; Tingting Yin; Fangfang Qiu; Zuguo Liu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-06-09       Impact factor: 2.416

4.  The influence of substrate topography on the migration of corneal epithelial wound borders.

Authors:  Bernardo Yanez-Soto; Sara J Liliensiek; Joshua Z Gasiorowski; Christopher J Murphy; Paul F Nealey
Journal:  Biomaterials       Date:  2013-09-07       Impact factor: 12.479

5.  A hyaluronan hydrogel scaffold-based xeno-free culture system for ex vivo expansion of human corneal epithelial stem cells.

Authors:  D Chen; Y Qu; X Hua; L Zhang; Z Liu; S C Pflugfelder; D-Q Li
Journal:  Eye (Lond)       Date:  2017-02-17       Impact factor: 3.775

6.  Corneal stromal bioequivalents secreted on patterned silk substrates.

Authors:  Jian Wu; Jelena Rnjak-Kovacina; Yiqin Du; Martha L Funderburgh; David L Kaplan; James L Funderburgh
Journal:  Biomaterials       Date:  2014-02-03       Impact factor: 12.479

7.  Corneal stromal stem cells versus corneal fibroblasts in generating structurally appropriate corneal stromal tissue.

Authors:  Jian Wu; Yiqin Du; Mary M Mann; James L Funderburgh; William R Wagner
Journal:  Exp Eye Res       Date:  2014-01-15       Impact factor: 3.467

8.  Human corneal stromal stem cells exhibit survival capacity following isolation from stored organ-culture corneas.

Authors:  Alvena K Kureshi; James L Funderburgh; Julie T Daniels
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-21       Impact factor: 4.799

9.  Lymphocyte function-associated antigen-1-dependent inhibition of corneal wound healing.

Authors:  Zhijie Li; Alan R Burns; C Wayne Smith
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

10.  [A comparative in vitro analysis of primary and immortalized keratocytes].

Authors:  L Kagan; P W Rieck
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.